Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Intravenous Infusion or Subcutaneous Injection Doses of BI 765250 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
Latest Information Update: 22 Nov 2024
Price :
$35 *
At a glance
- Drugs BI 765250 (Primary) ; BI 765250 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 19 Sep 2024 Status changed from active, no longer recruiting to completed.
- 02 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2023 Planned End Date changed from 30 Jun 2024 to 16 Sep 2024.